The European Commission authorized the transaction without conditions.

The tender offer is being made pursuant to an Provide to Purchase, dated Jan. 27, 2009, and in connection with the Plan and Agreement of Merger, dated Jan. 11, 2009, entered into by and among Abbott, Rainforest Acquisition Inc., a possessed subsidiary of Abbott wholly, and AMO, which AMO and Abbott announced about Jan. 12, 2009.. Abbott receives European clearance about acquisition of Advanced Medical Optics Abbott has announced that it has received merger control clearance from the European Commission for its acquisition of Advanced Medical Optics through a cash tender offer for the outstanding shares of common share of AMO. The European Commission authorized the transaction without conditions.There is a clear and compelling need for a novel system for the treatment of unhappiness, and ALKS 5461 reflects a new approach based on modulation of the opioid system in the brain. .

Barbara Fischer, Ph.D., Ulrik Lassen, Ph.D., Jann Mortensen, Dr.Med.Sci.D., Annika Loft, Ph.D., Anne Bertelsen, M.D., Jesper Ravn, M.D., Paul Clementsen, Dr.Med.Sci.D., Klaus Larsen, M.D., Torben Rasmussen, Ph.D., Susanne Keiding, Dr.Med.Sci., Asger Dirksen, Dr.Med.Sci., Oke Gerke, Ph.D., Birgit Skov, Dr.Med.Sci., Ida Steffensen, Ph.D., Hanne Hansen, M.D., Peter Vilmann, Dr.Med.Sci., Grete Jacobsen, Dr.Med.Sci., Vibeke Backer, Dr.Med.Sci.D., Jesper Pedersen, Dr.Med.Sci., Henrik Madsen, M.D., Henrik Nielsen, Dr.Med.Sci.Med.Sci.5 The advantage is situated mainly on a far more accurate assignment of tumor stage also to a smaller extent on defining the lymph-node stage .5-7 Whether the improved diagnostic accuracy improves management of the disease is unknown.